Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Microbix Biosystms J (TSE:MBX)
TSX:MBX
RESEARCH TOOLSreports
Holding TSE:MBX?
Track your performance easily
MBX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.23 - C$0.45
Previous CloseC$0.32
Volume1.70K
Average Volume (3M)90.71K
Market Cap
C$42.74M
Enterprise ValueC$36.29M
Total Cash (Recent Filing)C$12.81M
Total Debt (Recent Filing)C$6.36M
Price to Earnings (P/E)8.5
Beta-0.12
Next Earnings
Dec 19, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding137,417,293
10 Day Avg. Volume325,488
30 Day Avg. Volume90,706
Standard Deviation0.13
R-Squared0.01
Alpha0.00962
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)1.85
Price to Cash Flow (P/CF)7.70
P/FCF Ratio17.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.80Price Target Upside153.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Microbix Biosystms News
PremiumCompany Announcements
Microbix Unveils Novel HSV Diagnosis Enhancement
PremiumCompany Announcements
Microbix Secures Key EU Accreditations for QAPs
PremiumCompany Announcements
Microbix Biosystems to Present at Investment Conference
PremiumCompany Announcements
Microbix Biosystems Posts Strong Q3 Financials
PremiumCompany Announcements
Microbix Biosystems Gears Up for Q3 2024 ResultsPremiumCompany Announcements
Microbix Unveils Innovative HCV Test Control
PremiumCompany Announcements
Microbix Biosystems Unveils Major Expansions
PremiumCompany Announcements
Microbix Boosts Antigen Production CapabilitiesBulls Say, Bears Say
Bulls Say
Financial PerformanceAdjusted EBITDA increased 103% to $0.86M due to the higher revenues and gross margin.
Product PerformanceAntigen sales were up 37% to $4.1M as this product line continues to recover from a pandemic pullback.
Revenue GrowthTotal revenues increased 34% year-over-year.
Bears Say
Client RelationsA major QAPs client, QuidelOrtho, withdrew its 510(k) submission for its Savanna four-virus respiratory test due to performance issues.
RevenueTotal revenues decreased 9% mainly due to a $1.3M Kinlytic milestone received the prior year.
SalesAntigen sales represented a quarter-over-quarter decrease of 20% due in part to timing of large customer orders.
---
Options Prices
Currently, No data available
---
Ownership Overview
MBX FAQ
What was Microbix Biosystms J’s price range in the past 12 months?
Microbix Biosystms J lowest stock price was C$0.23 and its highest was C$0.45 in the past 12 months.
What is Microbix Biosystms J’s market cap?
Currently, no data Available
When is Microbix Biosystms J’s upcoming earnings report date?
Microbix Biosystms J’s upcoming earnings report date is Dec 19, 2024 which is in 41 days.
How were Microbix Biosystms J’s earnings last quarter?
Microbix Biosystms J released its earnings results on Aug 14, 2024. The company reported C$0.002 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.002.
Is Microbix Biosystms J overvalued?
According to Wall Street analysts Microbix Biosystms J’s price is currently Undervalued.
Does Microbix Biosystms J pay dividends?
Microbix Biosystms J does not currently pay dividends.
What is Microbix Biosystms J’s EPS estimate?
Microbix Biosystms J’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microbix Biosystms J have?
Microbix Biosystms J has 135,674,130 shares outstanding.
What happened to Microbix Biosystms J’s price movement after its last earnings report?
Microbix Biosystms J reported an EPS of C$0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Microbix Biosystms J?
Currently, no hedge funds are holding shares in TSE:MBX
---
Microbix Biosystms Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$0.80 (153.97% Upside)
C$0.80 (153.97% Upside)
Insider Transactions
Sold Shares
Worth C$72.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.52%
12-Months-Change
Fundamentals
Return on Equity
20.04%
Trailing 12-Months
Asset Growth
10.02%
Trailing 12-Months
Company Description
Microbix Biosystms J
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company operates in two industries: the development, manufacturing, and distribution of cell-based products and technology and, the provision of the facility, technical and production personnel for contract research and development. Microbix operates in three principal geographical areas: North America, Europe and in other foreign countries. It derives most of its revenue from Europe.
---
MBX Stock 12 Month Forecast
Average Price Target
C$0.80
▲(153.97% Upside)
Technical Analysis
Best Analysts Covering MBX
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-14.92%
reiterated a buy rating 3 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.92% per trade.
---